Freenome Stock

Multiomics Platform for Early Disease Screening

Sign up today and learn more about Freenome Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2015

Notable Investors

Andreessen Horowitz

Headquarters

South San Francisco CA, US

Total Funding

$77.5M

About Freenome Stock

Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.

Investors

Funding History

October 2015$800K
June 2016$5.6M
August 2017$72.0M
June 2019$165M
July 2020$270M

Management

Chief Executive Officer

Mike Nolan

Chief Financial Officer

William Quirk

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo